Guardant Complete Guardant Complete™

Testing Across the Continuum of Cancer

A Fast CGP Panel with Guideline-Recommended Actionable Biomarkers

Our Guardant360 CDx test is our FDA-approved liquid biopsy that provides results in 7 days upon sample receipt in the laboratory to inform treatment decisions.1 

Lab technician handles a blood vial.

Liquid Comprehensive Genomic Profiling with an Expanded Panel of Biomarkers

The Guardant360 liquid biopsy test helps find additional treatment options with an expanded panel of biomarkers.

The Only Tissue Comprehensive Genomic Profiling with AI-powered PD-L1 Detection

Our Guardant360 TissueNext tissue biopsy test finds actionable information when tissue testing is appropriate. The test leverages our AI-powered TPS analyser to improve PD-L1 detection by >20% in NSCLC.2,3

The only tissue comprehensive genomic profiling with AI-powered PD-L1 detection

Our Guardant360 TissueNext tissue biopsy test finds actionable information when tissue testing is appropriate. The test leverages our AI-powered scoring algorithm to improve PD-L1 detection by >20% in NSCLC.1,2 * Guardant360 TissueNext has broad commercial and Medicare coverage for advanced solid tumors.

Learn more
*compared to manual pathologist interpretation in the most challenging cases in NSCLC
  • Guardant360 TissueNext Assay Specifications. Guardant Health Inc. Redwood City, CA.
  • Data on file. Guardant Health, Inc. Redwood City, CA.
Guardant Reveal Box

Minimal Residual Disease Detection and Recurrence Monitoring

Guardant Reveal is a blood-only test without tissue baseline that detects circulating tumor DNA (ctDNA) for minimal residual disease (MRD) assessment in early-stage colorectal, breast, and lung cancers. In addition to detection of MRD, Guardant Reveal is also available to monitor recurrence in previously diagnosed patients.

The Only Tissue-Free Biopsy to Measure Treatment Response

Our Guardant360 Response test is the first tissue-free biopsy that enables doctors to view molecular response, or changes in circulating tumor DNA (ctDNA) levels, to get an early indication of patient response to immunotherapy or targeted therapy for advanced stage solid tumors. Studies show the Guardant360 Response test can predict treatment response 8 weeks earlier than current standard-of-care imaging.4-13

Request a Test Kit

Order Guardant Health AMEA test kits online.

Order Now

  1. Fastest average turnaround time from sample receipt to results based on stated average turnaround times from Integra Connect data.
  2. Guardant360(™) TissueNext Assay Specifications. Guardant Health Inc. Redwood City, CA.
  3. Data on file. Guardant Health, Inc. Redwood City, CA.
  4. Raja R, Kuziora M, Philip Z. Brohawn PZ, et al. Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab. Clin Cancer Res; 2018: 24(24): 6212-6222. DOI: 10.1158/1078-0432.CCR-18-0386.
  5. Aggarwal C,Thompson JC, Chien A, et al. Dynamic monitoring of circulating tumor DNA next-generation gene sequencing as a predictive biomarker of response and progression-free survival after pembrolizumab monotherapy in patients with advanced NSCLC.J Clin Oncol; 2019: 37:15 suppl, 3040-3040. DOI:10.1200/JCO.2019.37.15.
  6. Kim ST, Cristescu R, Bass AJ, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med; 2018: 24(9):1449-1458. DOI: 10.1038/s41591-018-0101-z.
  7. Shaw AT, Martini JF, Besse B, et al. Early circulating tumor (ct)DNA dynamics and efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol; 2019: 37:15_suppl, 9019-9019. DOI: 10.1200/JCO.2019.37.15.
  8. Pascual J, Cutts RJ, Kingston B, et al. Assessment of early ctDNA dynamics to predict efficacy of targeted therapies in metastatic breast cancer: Results from plasmaMATCH trial [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS5-02.DOI: 10.1158/1538-7445.SABCS20-PS5-02.
  9. Mack PC, Redman MW, Moon J, et al. Residual circulating tumor DNA (ctDNA) after two months of therapy to predict progression-free and overall survival in patients treated on S1403 with afatinib +/- cetuximab.J Clin Oncol; 2020: 38:15_suppl, 9532-9532. DOI: 10.1200/JCO.2020.38.15.
  10. Maron SB, Chatila WK, Millang BM, et al, Pembrolizumab with trastuzumab and chemotherapy (PTC) in HER2-positive metastatic esophagogastric cancer (mEG): Plasma and tumor-based biomarker analysis. J Clin Oncol; 2020: 38:15_suppl, 4559-4559. DOI: 10.1200/JCO.2020.38.15.
  11. Modi S, Park H, Murthy RK, et al. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study. J Clin Oncol; 2020: 38(17):1887-1896. DOI: 10.1200/JCO.19.02318.
  12. Zhang Q, Luo J, Wu S, et al. Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. Cancer Discov; 2020: 10:12, 1842-1853. DOI: 10.1158/2159-8290.CD-20-0047.
  13. Thompson JC, Carpenter EL, Silva BA, et al. Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy. JCO Precis; 2021: 5, 510-524. DOI: 10.1200/PO.20.0032.